318 related articles for article (PubMed ID: 18585835)
1. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial.
Dussol B; Morange S; Burtey S; Indreies M; Cassuto E; Mourad G; Villar E; Pouteil-Noble C; Karaaslan H; Sichez H; Lasseur C; Delmas Y; Nogier MB; Fathallah M; Loundou A; Mayor V; Berland Y
Am J Kidney Dis; 2008 Oct; 52(4):699-705. PubMed ID: 18585835
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of 'rescue therapy' with mycophenolate mofetil in resistant primary glomerulonephritis--a multicenter study.
Segarra A; Amoedo ML; Martinez Garcia JM; Pons S; Praga M; Garcia EI; Alonso JC; Gascó JM; Pou L; Piera L
Nephrol Dial Transplant; 2007 May; 22(5):1351-60. PubMed ID: 17311833
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial.
Hou JH; Le WB; Chen N; Wang WM; Liu ZS; Liu D; Chen JH; Tian J; Fu P; Hu ZX; Zeng CH; Liang SS; Zhou ML; Zhang HT; Liu ZH
Am J Kidney Dis; 2017 Jun; 69(6):788-795. PubMed ID: 28215945
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide.
Branten AJ; du Buf-Vereijken PW; Vervloet M; Wetzels JF
Am J Kidney Dis; 2007 Aug; 50(2):248-56. PubMed ID: 17660026
[TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy.
Hogg RJ; Bay RC; Jennette JC; Sibley R; Kumar S; Fervenza FC; Appel G; Cattran D; Fischer D; Hurley RM; Cerda J; Carter B; Jung B; Hernandez G; Gipson D; Wyatt RJ
Am J Kidney Dis; 2015 Nov; 66(5):783-91. PubMed ID: 26209543
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Mycophenolate Mofetil versus Cyclosporine as Combination Therapy with Low Dose Corticosteroids in High-risk Patients with Idiopathic Membranous Nephropathy: a Multicenter Randomized Trial.
Choi JY; Kim DK; Kim YW; Yoo TH; Lee JP; Chung HC; Cho KH; An WS; Lee DH; Jung HY; Cho JH; Kim CD; Kim YL; Park SH
J Korean Med Sci; 2018 Feb; 33(9):e74. PubMed ID: 29441742
[TBL] [Abstract][Full Text] [Related]
7. Use of mycophenolate mofetil in resistant membranous nephropathy.
Miller G; Zimmerman R; Radhakrishnan J; Appel G
Am J Kidney Dis; 2000 Aug; 36(2):250-6. PubMed ID: 10922302
[TBL] [Abstract][Full Text] [Related]
8. A comparison of a standard-dose prednisone regimen and mycophenolate mofetil combined with a lower prednisone dose in Chinese adults with idiopathic nephrotic syndrome who were carriers of hepatitis B surface antigen: a prospective cohort study.
Li X; Tian J; Wu J; He Q; Li H; Han F; Li Q; Chen Y; Ni Q; Chen J
Clin Ther; 2009 Apr; 31(4):741-50. PubMed ID: 19446147
[TBL] [Abstract][Full Text] [Related]
9. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome.
Chan TM; Lin AW; Tang SC; Qian JQ; Lam MF; Ho YW; Tse KC; Chan KW; Lai KN; Tang CS
Nephrology (Carlton); 2007 Dec; 12(6):576-81. PubMed ID: 17995584
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases.
Kasitanon N; Petri M; Haas M; Magder LS; Fine DM
Lupus; 2008 Jan; 17(1):40-5. PubMed ID: 18089682
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil treatment for therapy-resistant glomerulopathies.
Sahin GM; Sahin S; Kantarci G; Ergin H
Nephrology (Carlton); 2007 Jun; 12(3):285-8. PubMed ID: 17498124
[TBL] [Abstract][Full Text] [Related]
12. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy.
Karim MY; Pisoni CN; Ferro L; Tungekar MF; Abbs IC; D'Cruz DP; Khamashta MA; Hughes GR
Rheumatology (Oxford); 2005 Oct; 44(10):1317-21. PubMed ID: 16049051
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial.
Cattran DC; Appel GB; Hebert LA; Hunsicker LG; Pohl MA; Hoy WE; Maxwell DR; Kunis CL;
Kidney Int; 2001 Apr; 59(4):1484-90. PubMed ID: 11260412
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil in the treatment of glomerular diseases.
Grcevska L; Polenakovic M
Prilozi; 2007 Jul; 28(1):57-68. PubMed ID: 17921918
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy.
Liang Q; Li H; Xie X; Qu F; Li X; Chen J
Ren Fail; 2017 Nov; 39(1):512-518. PubMed ID: 28562168
[TBL] [Abstract][Full Text] [Related]
16. Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome.
Yap DY; Yu X; Chen XM; Lu F; Chen N; Li XW; Tang CS; Chan TM
Nephrology (Carlton); 2012 May; 17(4):352-7. PubMed ID: 22295934
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial.
Hiemstra TF; Walsh M; Mahr A; Savage CO; de Groot K; Harper L; Hauser T; Neumann I; Tesar V; Wissing KM; Pagnoux C; Schmitt W; Jayne DR;
JAMA; 2010 Dec; 304(21):2381-8. PubMed ID: 21060104
[TBL] [Abstract][Full Text] [Related]
18. Idiopathic membranous nephropathy in pediatric patients: presentation, response to therapy, and long-term outcome.
Chen A; Frank R; Vento S; Crosby V; Chandra M; Gauthier B; Valderrama E; Trachtman H
BMC Nephrol; 2007 Aug; 8():11. PubMed ID: 17683621
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil therapy for steroid-resistant IgA nephropathy with the nephrotic syndrome in children.
Kang Z; Li Z; Duan C; Wu T; Xun M; Ding Y; Zhang Y; Zhang L; Yin Y
Pediatr Nephrol; 2015 Jul; 30(7):1121-9. PubMed ID: 25773534
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study.
Walsh M; Solomons N; Lisk L; Jayne DR
Am J Kidney Dis; 2013 May; 61(5):710-5. PubMed ID: 23375819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
